Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0151744 (myocardial ischemia)
 31,282 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Results with a new anti-angina molecule (nifedipine: Adalat) in the long-term management of 28 patients with ischaemic heart disease are presented. The effectiveness of the drug was judged outstanding on the strength of its reduction of angina outstanding on the strength of its reduction of angina crises and consumption of NTG beads. Non side-effects were noted.
 ...
PMID:[Long-term clinical study of a new molecule (nifedipine) in ischemic cardiopathy]. 40 86

Effects of the new Ca++ antagonist nifedipine (Adalat) on coronary haemodynamics were studied in 8 patients with documented ischaemic heart disease. The continuous infusion thermodilution technique was used to measure cardiac venous blood flow. Sublingual application of 10 mg nifedipine caused a significant increase (16%) in myocardial blood flow and a decrease (18%) in coronary arteriolar resistance at rest, but not during a submaximal atrial pacing test. There was no change in coronary arteriovenous oxygen difference, myocardial oxygen consumption, oxygen consumption per unit of heart rate blood pressure index or left ventricular efficiency index. The effects on the coronary haemodynamics are discussed in relation to the simultaneous changes in general haemodynamics. Systolic aortic pressure was slightly reduced, significantly only at rest, while peripheral vascular resistance decreased and cardiac output increased also during atrial pacing. No change in free fatty acid metabolism was observed. It is concluded that nifedipine is a mild coronary vasodilator. No effect was observed on myocardial oxygen demand. The oxygen cost of left ventricular work was unchanged by the drug both at rest and during the submaximal stress test.
 ...
PMID:Effect of nifedipine (Adalat) on coronary haemodynamics in patients with coronary arteriosclerotic disease. 69 17

Nifangin (nifedipine), manufactured by the Laakepharmos Co., Finland, was used in 75 patients with congestive heart failure due to ischemic heart disease and chronic obstructive bronchitis. The effect of a single 20 mg dose and a course of treatment (60 mg daily for 18 days) was assessed by monitoring with the help of echocardiography, venous occlusion plethysmography, laser Doppler flowmetry as well as external respiration and blood gases partial tension measurement. In patients with chronic obstructive bronchitis, the drug was used in combination with cardiac glycosides and diuretics. A single dose of nifangin reduced regional vascular resistance by 33%, and increased volumetric blood flow rate by 51%. The treatment course increased the stroke index and the cardiac index (by 21 and 23%, respectively) and improved blood oxygenation and external respiration parameters. The absence of side effects makes nifangin one of the most effective vasodilating agents, indicated for patients with congestive heart failure.
 ...
PMID:[Effect of the calcium antagonist nifangin on hemodynamics in patients with congestive heart failure]. 267 59

Angina pectoris patients were divided into two groups of unstable angina and stable angina, platelet aggregation was measured at rest and after treadmill exercise tolerance, and then the effects before and after the administration of nifedipine (Adalat) were examined. As a result, no significant difference in platelet aggregation at rest was seen in either group between before and after the administration of nifedipine, but the acceleration of platelet aggregation response to exercise was significantly inhibited by nifedipine. Moreover, the extent of inhibition was more notable in unstable angina group. It was discussed that such an inhibitory effect of nifedipine on platelet aggregation response to exercise could be related to vasospasm and in its turn possibly takes part in the development of myocardial ischemia.
 ...
PMID:Effect of the calcium antagonistic agent nifedipine on platelet aggregation response to exercise in patients with angina pectoris. 689 98

38 patients with ischemic heart disease (IHD) and sick sinus syndrome (SSS) received combined therapy with nifedipine (Corinfar-Retard) and talinolol (Cordanum). The former drug had a positive chronotropic effect on the heart, the latter's chronotropic effect was slightly negative. All the patients had sinus bradycardia and ectopic arrhythmia which needed therapeutic correction: supraventricular and ventricular extrasystoles, fibrillation paroxysms or/and atrial flutter, paroxysmal supraventricular tachycardia, ventricular tachycardia. Cordanum was given in a dose 50 mg twice a day, Corinfar-Retard 20 mg twice a day for 16 days. 30 patients responded to the treatment. In addition to good subjective response, episodes of extrasystoles, paroxysms, flutter and fibrillation occurred much less frequently. Side effects resulted in the treatment discontinuation in 3 patients.
 ...
PMID:[The use of Cordanum in combination with Corinfar-Retard for the treatment of ectopic arrhythmias in the sick sinus syndrome in patients with ischemic heart disease]. 941 31

The three currently available channel-blocking agents, nifedipine (Adalat), diltiazem (Cardiazem), and verapamil (Isoptin), are all useful in treating a number of cardiovascular disorders, especially ischemic heart disease. Although they have a common mechanism of action, their cardiovascular effects and pharmacological properties differ considerably. Each drug, consequently, has specific clinical indications; these drugs are not easily interchangeable. Understanding their properties and effects allows the physician to choose the particular drug most suited to the patient's needs.
 ...
PMID:Selecting a calcium channel-blocking agent. 2126 15